Schizophrenia

When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Última revisão: 8 Oct 2025
Última atualização: 21 Mar 2025

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

  • auditory hallucinations
  • delusions
  • avolition
  • anhedonia
  • asocial behavior
  • affective blunting
  • alogia
  • cognitive deficits
  • somatization
Detalhes completos

Outros fatores diagnósticos

  • lack of insight (anosognosia)
  • bizarre or disorganized behavior
  • tangentiality and looseness of association (derailment)
  • circumstantiality
  • pressured speech
  • distractible speech
  • depression
  • suicidality
  • anxiety
  • elation
  • incongruent affect
  • verbigeration
  • perseveration
  • word salad
  • derealization
  • nonauditory hallucinations
  • déjà-vu
  • stilted goal-directed behaviors
  • catatonic symptoms
  • "soft" neurologic deficits
Detalhes completos

Fatores de risco

  • family history of schizophrenia
  • increasing paternal age
  • obstetric complications
  • cannabis use
  • low IQ
  • motor dysfunction
  • psychological stress
  • childhood abuse
  • migrant status
Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • clinical diagnosis
Detalhes completos

Investigações a serem consideradas

  • MRI/CT head
  • serum HIV enzyme-linked immunosorbent assay
  • serum rapid plasma reagin (RPR) test
  • CBC including absolute neutrophil count (ANC)
  • drug toxicology screen
  • BUN and electrolytes
  • liver function tests
  • thyroid-stimulating hormone
  • pregnancy test
  • genetic testing
Detalhes completos

Algoritmo de tratamento

Inicial

at risk of developing psychosis

AGUDA

acute psychotic episode

CONTÍNUA

chronic symptoms

treatment-resistant schizophrenia

Colaboradores

Consultores especialistas

Xiaoduo Fan, MD, MPH, MSc

Professor of Psychiatry

Director, UMass MIND

UMass Memorial Health/UMass Chan Medical School

Worcester

MA

Declarações

XF has received research support from Otsuka, Roche, Intra-Cellular Therapies, Avanir, and Janssen. XF holds a patent on "combination treatment for neuropsychiatric disorders" (USPTO patent # 11,331,319).

Agradecimentos

Dr Xiaoduo Fan would like to gratefully acknowledge Dr Adrian Preda and Dr Robert G. Bota, previous contributors to this topic.

Declarações

AP and RGB declare that they have no competing interests.

Revisores

David Taylor, PhD

Chief Pharmacist

South London and Maudsley NHS Foundation Trust

London

UK

Declarações

DT declares that he has no competing interests.

Joel Yager, MD

Professor

Department of Psychiatry

University of New Mexico School of Medicine

Albuquerque

NM

Declarações

JY declares that he has no competing interests.

Kemal Sagduyu, MD

Professor of Psychiatry

University of Missouri Kansas City

Kansas City

MO

Declarações

KS declares that he has no competing interests.

Créditos aos pareceristas

Os tópicos do BMJ Best Practice são constantemente atualizados, seguindo os desenvolvimentos das evidências e das diretrizes. Os pareceristas aqui listados revisaram o conteúdo pelo menos uma vez durante a história do tópico.

Declarações

As afiliações e declarações dos pareceristas referem--se ao momento da revisão.

Referências

Nossas equipes internas de editoria e de evidências trabalham em conjunto com colaboradores internacionais especializados e pares revisores para garantir que forneçamos acesso às informações o mais clinicamente relevantes possível.

Principais artigos

American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.Texto completo

American Psychiatric Association. ​The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Washington, DC: American Psychiatric Association; 2021.Texto completo

Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012 Jul;13(5):318-78. Resumo

Artigos de referência

Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
  • Diagnósticos diferenciais

    • Schizoaffective disorder
    • Schizophreniform disorder and brief psychotic disorder
    • Substance-induced psychotic disorder
    Mais Diagnósticos diferenciais
  • Diretrizes

    • Diagnostic and statistical manual of mental disorders, fifth edition (DSM-5-TR)
    • Evidence-based guidelines for the pharmacological treatment of schizophrenia
    Mais Diretrizes
  • Folhetos informativos para os pacientes

    Schizophrenia: what is it?

    Schizophrenia: questions to ask your doctor

    Mais Folhetos informativos para os pacientes
  • padlock-lockedConectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal